Clover Bio-B (02197) rose more than 7%. As of press release, it was up 7.14% to HK$0.75, with a turnover of HK$1,9181,000.
The Zhitong Finance app learned that Clover Bio-B (02197) rose more than 7%. As of press release, it had risen 7.14% to HK$0.75, with a turnover of HK$1,9181,000.
According to the news, respiratory viruses have been raging recently. Pediatricians in many hospitals are overcrowded, and respiratory diseases are frequent. According to experts, as the temperature drops, respiratory syncytial virus (RSV) has entered a season of high incidence. According to reports, RSV is an RNA virus that spreads through droplets and close contact. It is highly contagious. The symptoms are similar to influenza but are actually more serious: fever, cough, chest pain, asthma, and even difficulty breathing.
According to a previous research report by Guoxin Securities, the global RSV vaccine/antibody drug market is expected to reach the level of 10 billion US dollars. The bank notes that RSV has a higher burden of disease among infants, young children and the elderly. There are no commercial varieties listed in the domestic market, and many companies, such as Clover Biotech, are in the pre-clinical layout stage. According to reports, Clover Biotech has accelerated the clinical application and development of the SCB-1019 vaccine in China and globally, and the company expects to enter clinical phase I in the first half of 2024.